Shanghai RAAS halts trading for Haier Bio-Science merger

Shanghai RAAS Blood Products (SZSE: 002252) announced a trading halt starting December 23, 2024, pending a major asset restructuring. The company is planning a merger with Qingdao Haier Bio-Medical Co., Ltd. ("Haier Bio-Science") through a share swap, where Haier Bio-Science will issue A-shares to acquire all outstanding shares of Shanghai RAAS. The halt is expected to last no more than 10 trading days. Prior to the halt, Haier Bio-Science's affiliate, Haiyingkang (Qingdao) Medical Technology Co., Ltd., held a 20.02% stake, making it the largest shareholder. GRIFOLS, S.A. was the second largest shareholder with a 6.58% stake. The filing detailed the top ten shareholders and top ten public shareholders as of December 20, 2024.